686 related articles for article (PubMed ID: 27502297)
21. IL-4 Downregulates IL-1β and IL-6 and Induces GATA3 in Psoriatic Epidermal Cells: Route of Action of a Th2 Cytokine.
Onderdijk AJ; Baerveldt EM; Kurek D; Kant M; Florencia EF; Debets R; Prens EP
J Immunol; 2015 Aug; 195(4):1744-52. PubMed ID: 26170379
[TBL] [Abstract][Full Text] [Related]
22. Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10.
Zanin-Zhorov A; Weiss JM; Trzeciak A; Chen W; Zhang J; Nyuydzefe MS; Arencibia C; Polimera S; Schueller O; Fuentes-Duculan J; Bonifacio KM; Kunjravia N; Cueto I; Soung J; Fleischmann RM; Kivitz A; Lebwohl M; Nunez M; Woodson J; Smith SL; West RF; Berger M; Krueger JG; Ryan JL; Waksal SD
J Immunol; 2017 May; 198(10):3809-3814. PubMed ID: 28389592
[TBL] [Abstract][Full Text] [Related]
23. Secukinumab: IL-17A inhibition to treat psoriatic arthritis.
Speeckaert R; van Geel N; Lambert J; Claeys L; Delanghe JR; Speeckaert MM
Drugs Today (Barc); 2016 Nov; 52(11):607-616. PubMed ID: 28112279
[TBL] [Abstract][Full Text] [Related]
24. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
[TBL] [Abstract][Full Text] [Related]
25. Secukinumab: first global approval.
Sanford M; McKeage K
Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
27. Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis.
Cardner M; Tuckwell D; Kostikova A; Forrer P; Siegel RM; Marti A; Vandemeulebroecke M; Ferrero E
RMD Open; 2023 Jun; 9(2):. PubMed ID: 37321668
[TBL] [Abstract][Full Text] [Related]
28. Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha.
Ogilvie AL; Lüftl M; Antoni C; Schuler G; Kalden JR; Lorenz HM
Int J Immunopathol Pharmacol; 2006; 19(2):271-8. PubMed ID: 16831294
[TBL] [Abstract][Full Text] [Related]
29. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
Adams R; Maroof A; Baker T; Lawson ADG; Oliver R; Paveley R; Rapecki S; Shaw S; Vajjah P; West S; Griffiths M
Front Immunol; 2020; 11():1894. PubMed ID: 32973785
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor-associated dermatitis.
Cohen JN; Bowman S; Laszik ZG; North JP
J Am Acad Dermatol; 2020 Feb; 82(2):430-439. PubMed ID: 31859047
[TBL] [Abstract][Full Text] [Related]
31. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
Reich K; Papp KA; Matheson RT; Tu JH; Bissonnette R; Bourcier M; Gratton D; Kunynetz RA; Poulin Y; Rosoph LA; Stingl G; Bauer WM; Salter JM; Falk TM; Blödorn-Schlicht NA; Hueber W; Sommer U; Schumacher MM; Peters T; Kriehuber E; Lee DM; Wieczorek GA; Kolbinger F; Bleul CC
Exp Dermatol; 2015 Jul; 24(7):529-35. PubMed ID: 25828362
[TBL] [Abstract][Full Text] [Related]
32. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin.
Jansen PA; Rodijk-Olthuis D; Hollox EJ; Kamsteeg M; Tjabringa GS; de Jongh GJ; van Vlijmen-Willems IM; Bergboer JG; van Rossum MM; de Jong EM; den Heijer M; Evers AW; Bergers M; Armour JA; Zeeuwen PL; Schalkwijk J
PLoS One; 2009; 4(3):e4725. PubMed ID: 19266104
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-17A biomarker as a predictor for detection of early axial spondyloarthritis changes in patients with psoriasis.
Saif DS; El Tabl MA; Afifi N; Abdallah MS; El Hefnawy SM; Hassanein SA
Int J Rheum Dis; 2020 Dec; 23(12):1664-1669. PubMed ID: 33016599
[TBL] [Abstract][Full Text] [Related]
34. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
[TBL] [Abstract][Full Text] [Related]
35. IL-17 in cutaneous lupus erythematosus.
Tanasescu C; Balanescu E; Balanescu P; Olteanu R; Badea C; Grancea C; Vagu C; Bleotu C; Ardeleanu C; Georgescu A
Eur J Intern Med; 2010 Jun; 21(3):202-7. PubMed ID: 20493423
[TBL] [Abstract][Full Text] [Related]
36. The human IL-17A/F heterodimer regulates psoriasis-associated genes through IκBζ.
Bertelsen T; Iversen L; Johansen C
Exp Dermatol; 2018 Sep; 27(9):1048-1052. PubMed ID: 29938836
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.
Russell CB; Rand H; Bigler J; Kerkof K; Timour M; Bautista E; Krueger JG; Salinger DH; Welcher AA; Martin DA
J Immunol; 2014 Apr; 192(8):3828-36. PubMed ID: 24646743
[TBL] [Abstract][Full Text] [Related]
38. Secukinumab for the treatment of psoriatic arthritis.
Baronaite Hansen R; Kavanaugh A
Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
[TBL] [Abstract][Full Text] [Related]
40. MCPIP1/Regnase-1 Restricts IL-17A- and IL-17C-Dependent Skin Inflammation.
Monin L; Gudjonsson JE; Childs EE; Amatya N; Xing X; Verma AH; Coleman BM; Garg AV; Killeen M; Mathers A; Ward NL; Gaffen SL
J Immunol; 2017 Jan; 198(2):767-775. PubMed ID: 27920272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
